VX-984

Developed for: neoplastic disease or syndrome
Investigated by: EMD Serono Research & Development Institute, Inc. · Merck KGaA, Darmstadt, Germany

today NCT02644278 · Ph 1

201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT02644278	Feb 2016 → Oct 2017	neoplastic disease or syndrome	EMD Serono Research & Development Institute, Inc.	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	VX-984	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02644278 ↗
Route	Oral	“Participants received VX-984 orally” NCT02644278 ↗